CAS: 875337-44-3 - N-[(3-fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide
Formula:C26H20FN5O2S2
InChI:InChI=1/C26H20FN5O2S2/c1-32-14-20(29-15-32)23-13-19-25(36-23)22(9-10-28-19)34-21-8-7-17(12-18(21)27)30-26(35)31-24(33)11-16-5-3-2-4-6-16/h2-10,12-15H,11H2,1H3,(H2,30,31,33,35)
- Synonyms:
- Mgcd-265
N-[[[3-Fluoro-4-[[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy]phenyl]amino]thioxomethyl]benzeneacetamide
CAS:875337-44-3
Formula:
C26H20FN5O2S2
Purity:
%
Color and Shape:
Solid
Molecular weight:
517.5977
Ref: IN-DA003AKW
10mg | 166.00 € | ||
25mg | 201.00 € | ||
50mg | 319.00 € | ||
100mg | 481.00 € |
Estimated delivery in United States, on Monday 16 Dec 2024
MGCD-265 analog
CAS:875337-44-3
Glesatinib, an oral tyrosine kinase inhibitor, targets c-Met and VEGFR2 with IC50s of 29 nM …
Formula:
C26H20FN5O2S2
Purity:
98.06% - 98.68%
Color and Shape:
Solid
Molecular weight:
517.6
- Inhibitors
- Angiogenesis
- Apoptosis
- VEGFR
- See more categories
- c-Met/HGFR
- Tyrosine and Impurities
Ref: TM-T6351
2mg | 35.00 € | ||
5mg | 51.00 € | ||
10mg | 82.00 € | ||
25mg | 159.00 € | ||
50mg | 246.00 € | ||
100mg | To inquire | ||
1mL*10mM (DMSO) | 60.00 € |
Estimated delivery in United States, on Monday 23 Dec 2024
MGCD 265
CAS:875337-44-3
Inhibits MET, VEGFR1-3, Tie and Ron tyrosine kinases; antineoplastic
Formula:
C26H20FN5O2S2
Purity:
Min. 95%
Molecular weight:
517.60 g/mol
Ref: 3D-FF41064
10mg | 155.00 € | ||
25mg | 232.00 € |
Estimated delivery in United States, on Friday 27 Dec 2024
MGCD-265
Controlled ProductCAS:875337-44-3
Formula:
C26H20FN5O2S2
Color and Shape:
Neat
Molecular weight:
517.598
Ref: TR-M198700
250mg | 5,356.00 € |
Estimated delivery in United States, on Tuesday 28 Jan 2025